NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027

MARKET OUTLOOK
The immunohistochemistry market in North America is projected to develop at a CAGR of 7.19% during the forecast period of 2019-2027.
The countries of the United States and Canada have been considered for analysis in the report on North America’s immunohistochemistry market.
The United States immunohistochemistry market is developing and expanding at a significant pace. The market in the country is mainly driven by the rising prevalence of autoimmune diseases along with the pervasiveness of cancer. Cancer and Alzheimer’s disease, which are on the constant rise, have received the largest portion of the funding made by the United States government. A cancer-focused precision medicine initiative was launched in the year 2017 that would enhance the opportunities considering the IVD space. The researchers in the United States have identified 80-100 various autoimmune diseases and also expect around 40 additional diseases that consist of the factors of autoimmune basis as these types of diseases are chronic in nature, which in turn, could be life-threatening for an individual.
COMPETITIVE OUTLOOK
The notable companies operating in the immunohistochemistry market are Merck Millipore, Bio SB, PerkinElmer, Inc., Abcam Plc, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc., Danaher Corporation, Abbott Laboratories, BioGenex, Histologix, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Siemens AG Healthcare and Agilent Technologies, Inc.

TABLE OF CONTENT
1. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. HISTORY OF IMMUNOHISTOCHEMISTRY
2.2. VALUE CHAIN OUTLOOK
2.3. KEY INSIGHTS
2.4. REGULATORY OUTLOOK
2.4.1. REGULATIONS IN THE UNITED STATES
2.5. MARKET ATTRACTIVENESS MATRIX
2.6. MARKET DRIVERS
2.6.1. IN-VITRO TECHNOLOGICAL ADVANCEMENTS
2.6.2. INCREASING CANCER OCCURRENCE
2.6.3. SWELLING HEALTHCARE SPENDING
2.6.4. RISING GERIATRIC POPULATION
2.6.5. INCREASING USE OF POC TESTING
2.7. MARKET RESTRAINTS
2.7.1. RESTRICTIONS OF CLOSED SYSTEMS
2.7.2. REIMBURSEMENT ISSUES
2.8. MARKET OPPORTUNITIES
2.8.1. INCREASING USE OF BIOMARKERS FOR DISEASE DIAGNOSIS
2.8.2. TECHNOLOGICAL ADVANCEMENTS
2.9. MARKET CHALLENGES
2.9.1. STRINGENT REGULATIONS
2.9.2. HIGH MAINTENANCE COST INFLUENCING THE MARKET GROWTH
3. IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK - BY PRODUCTS
3.1. ANTIBODIES
3.1.1. PRIMARY ANTIBODIES
3.1.2. SECONDARY ANTIBODIES
3.2. EQUIPMENT
3.2.1. SLIDE STAINING SYSTEMS
3.2.2. TISSUE MICROARRAYS
3.2.3. TISSUE PROCESSING SYSTEMS
3.2.4. SLIDE SCANNERS
3.2.5. OTHER EQUIPMENT
3.3. REAGENTS
3.3.1. HISTOLOGICAL STAINS
3.3.2. BLOCKING SERA AND REAGENTS
3.3.3. CHROMOGENIC SUBSTRATES
3.3.4. FIXATION REAGENTS
3.3.5. STABILIZERS
3.3.6. ORGANIC SOLVENTS
3.3.7. PROTEOLYTIC ENZYMES
3.3.8. DILUENTS
3.4. KITS
4. IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK - BY APPLICATIONS
4.1. DIAGNOSTICS
4.1.1. CANCER
4.1.2. INFECTIOUS DISEASES
4.1.3. CARDIOVASCULAR DISEASE
4.1.4. AUTOIMMUNE DISEASES
4.1.5. DIABETES MELLITUS
4.1.6. NEPHROLOGICAL DISEASES
4.2. DRUG TESTING
5. IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK - BY END-USERS
5.1. HOSPITALS AND DIAGNOSTIC LABORATORIES
5.2. RESEARCH INSTITUTES
5.3. OTHER END-USERS
6. IMMUNOHISTOCHEMISTRY (IHC) MARKET - NORTH AMERICA
6.1. COUNTRY ANALYSIS
6.1.1. THE UNITED STATES
6.1.2. CANADA
7. COMPETITIVE LANDSCAPE
7.1. ABBOTT LABORATORIES
7.2. ABCAM PLC
7.3. AGILENT TECHNOLOGIES, INC.
7.4. BIOGENEX
7.5. BIO-RAD LABORATORIES, INC.
7.6. BIO SB
7.7. CELL SIGNALING TECHNOLOGY, INC.
7.8. DANAHER CORPORATION
7.9. F. HOFFMANN-LA ROCHE AG
7.10. HISTOLOGIX
7.11. MERCK MILLIPORE
7.12. PERKINELMER, INC.
7.13. SIEMENS AG HEALTHCARE
7.14. THERMO FISHER SCIENTIFIC, INC.
8. METHODOLOGY AND SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY





TABLE LIST
TABLE 1 NORTH AMERICA MARKET FOR IMMUNOHISTOCHEMISTRY BY REGION 2019-2027 ($ MILLION)
TABLE 2 CANCER MARKERS USED IN DIAGNOSIS AND TREATMENT
TABLE 3 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 4 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES BY TYPE 2019-2027 ($ MILLION)
TABLE 5 CLINICALLY IMPORTANT MONOCLONAL ANTIBODIES
TABLE 6 SECONDARY ANTIBODY SELECTIONS
TABLE 7 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT BY TYPES 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS BY TYPE 2019-2027 ($ MILLION)
TABLE 9 HISTOLOGY STAINS AND ITS CATEGORIES
TABLE 10 COMMON FIXATIVES AND THEIR GENERAL TARGET ANTIGENS
TABLE 11 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN KITS 2019-2027 ($ MILLION)
TABLE 12 KIT COMPONENTS ARE AVAILABLE FOR IHC OPTIMIZATION
TABLE 13 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTICS BY TYPE 2019-2027 ($ MILLION)
TABLE 15 SELECTED INFECTIOUS ETIOLOGIES OF AUTOIMMUNE DISEASES
TABLE 16 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY 2019-2027 ($ MILLION)



FIGURE LIST
FIGURE 1 NORTH AMERICA MARKET FOR IMMUNOHISTOCHEMISTRY 2019-2027 ($ MILLION)
FIGURE 2 HISTORY OF IMMUNOHISTOCHEMISTRY
FIGURE 3 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 4 NORTH AMERICA ANTIBODIES MARKET IN PRIMARY ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 5 NORTH AMERICA ANTIBODIES MARKET IN SECONDARY ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 6 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT 2019-2027 ($ MILLION)
FIGURE 7 NORTH AMERICA EQUIPMENT MARKET IN SLIDE STAINING SYSTEMS 2019-2027 ($ MILLION)
FIGURE 8 NORTH AMERICA EQUIPMENT MARKET IN TISSUE MICROARRAYS 2019-2027 ($ MILLION)
FIGURE 9 NORTH AMERICA EQUIPMENT MARKET IN TISSUE PROCESSING SYSTEMS 2019-2027 ($ MILLION)
FIGURE 10 NORTH AMERICA EQUIPMENT MARKET IN SLIDE SCANNERS 2019-2027 ($ MILLION)
FIGURE 11 NORTH AMERICA EQUIPMENT MARKET IN OTHER EQUIPMENT 2019-2027 ($ MILLION)
FIGURE 12 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS 2019-2027 ($ MILLION)
FIGURE 13 NORTH AMERICA REAGENTS MARKET IN HISTOLOGICAL STAINS 2019-2027 ($ MILLION)
FIGURE 14 NORTH AMERICA REAGENTS MARKET IN BLOCKING SERA AND REAGENTS 2019-2027 ($ MILLION)
FIGURE 15 NORTH AMERICA REAGENTS MARKET IN CHROMOGENIC SUBSTRATES 2019-2027 ($ MILLION)
FIGURE 16 NORTH AMERICA REAGENTS MARKET IN FIXATION REAGENTS 2019-2027 ($ MILLION)
FIGURE 17 NORTH AMERICA REAGENTS MARKET IN STABILIZERS 2019-2027 ($ MILLION)
FIGURE 18 NORTH AMERICA REAGENTS MARKET IN ORGANIC SOLVENTS 2019-2027 ($ MILLION)
FIGURE 19 NORTH AMERICA REAGENTS MARKET IN PROTEOLYTIC ENZYMES 2019-2027 ($ MILLION)
FIGURE 20 NORTH AMERICA REAGENTS MARKET IN DILUENTS 2019-2027 ($ MILLION)
FIGURE 21 PHASES OF HISTOLOGICAL STAINING
FIGURE 22 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN KITS 2019-2027 ($ MILLION)
FIGURE 23 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTICS 2019-2027 ($ MILLION)
FIGURE 24 NORTH AMERICA DIAGNOSTICS MARKET IN CANCER 2019-2027 ($ MILLION)
FIGURE 25 NORTH AMERICA DIAGNOSTICS MARKET IN INFECTIOUS DISEASES 2019-2027 ($ MILLION)
FIGURE 26 NORTH AMERICA DIAGNOSTICS MARKET IN CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
FIGURE 27 NORTH AMERICA DIAGNOSTICS MARKET IN AUTOIMMUNE DISEASES 2019-2027 ($ MILLION)
FIGURE 28 NORTH AMERICA DIAGNOSTICS MARKET IN DIABETES MELLITUS 2019-2027 ($ MILLION)
FIGURE 29 NORTH AMERICA DIAGNOSTICS MARKET IN NEPHROLOGICAL DISEASES 2019-2027 ($ MILLION)
FIGURE 30 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN DRUG TESTING 2019-2027 ($ MILLION)
FIGURE 31 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN HOSPITALS AND DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 32 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN RESEARCH INSTITUTES 2019-2027 ($ MILLION)
FIGURE 33 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET IN OTHER END-USERS 2019-2027 ($ MILLION)
FIGURE 34 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 35 THE UNITED STATES IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 36 CANADA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)